NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro

被引：1
|
作者：
Boerner, Joanna [1 ]
Ma, Sue [1 ]
Compton, Teresa [1 ]
Lin, Kai [1 ]
机构：
[1] Novartis Inst Biomed Res, Cambridge, MA 02139 USA
来源：
ANTIVIRAL RESEARCH | 2007年 / 74卷 / 03期
关键词：
D O I：
10.1016/j.antiviral.2007.01.081
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
73
引用
收藏
页码：A57 / A57
页数：1
相关论文
共 20 条
  • [1] NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro
    Lin, K.
    Boerner, J.
    Ma, S.
    Compton, T.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S230 - S230
  • [2] A COMBINATION OF A NOVEL CYCLOPHILIN INHIBITOR AND A NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR SYNERGISTICALLY INHIBITS VIRAL REPLICATION AND SUPPRESSES THE EMERGENCE OF RESISTANCE
    Owens, Christopher M.
    Poon, Tiffany W.
    Long, Jiang
    Qiu, Yao-Ling
    Wang, Guoqiang
    Jiang, Lijuan
    Or, Yat Sun
    HEPATOLOGY, 2009, 50 (04) : 1042A - 1042A
  • [3] Nim811 inhibits HCV replication through interaction with cyclophilins
    Tao, Jianshi
    Jogger, Cheryl
    Shen, Xiaoyu
    Lin, Kai
    Lai, Choi
    Yip, Tiong
    Brown, Kara
    Wiedmann, Brigitte
    Voshol, Hans
    Muller, Dieter
    Van Oostrum, Jan
    Lee, Kwangho
    Hunziker, Juerg
    Ryder, Neil S.
    Cooreman, Michael P.
    Weidmann, Beat
    GASTROENTEROLOGY, 2006, 130 (04) : A829 - A829
  • [4] NIM811: An HCV replication inhibitor of novel mechanism, exhibits potent antiviral activities alone or in combination with a non-nucleoside HCV polymerase inhibitor
    Boerner, JE
    Ma, S
    Yip, CLT
    Cooreman, MP
    Compton, T
    Lin, K
    ANTIVIRAL RESEARCH, 2006, 70 (01) : A34 - A35
  • [5] SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS
    Ke, J.
    Lawitz, E.
    Rozier, R.
    Marbury, T.
    Nguyen, N.
    Serra, D.
    Dole, K.
    Praestgaard, J.
    Huang, M.
    Evans, T.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S229 - S229
  • [6] Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
    Lawitz, Eric
    Godofsky, Eliot
    Rouzier, Regine
    Marbury, Thomas
    Tuan Nguyen
    Ke, June
    Huang, MeiMei
    Praestgaard, Jens
    Serra, Denise
    Evans, Thomas G.
    ANTIVIRAL RESEARCH, 2011, 89 (03) : 238 - 245
  • [7] NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon
    Ma, Sue
    Boerner, Joanna E.
    TiongYip, ChoiLai
    Weidmann, Beat
    Ryder, Neil S.
    Cooreman, Michael P.
    Lin, Kai
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) : 2976 - 2982
  • [8] Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance
    Mathy, Joanna E.
    Ma, Sue
    Compton, Teresa
    Lin, Kai
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) : 3267 - 3275
  • [9] HCV polymerase (NM107) and protease (boceprevir) inhibitors in combination show enhanced activity and suppression of resistance in the replicon system
    Standring, David N.
    Bichko, Vadim
    Chase, Robert
    LaColla, Max
    Lallos, Lisa
    Skelton, Angela
    Soukasakos, Mary
    Tausek, M.
    Tong, Xiao
    Ralston, Robert
    HEPATOLOGY, 2007, 46 (04) : 857A - 857A
  • [10] IN VIVO AND IN VITRO RESISTANCE TO SILIBININ, A COMPONENT OF SILYMARIN AND POTENT INHIBITOR OF HCV REPLICATION
    Chevaliez, S.
    Ahmed-Belkacem, A.
    Soulier, A.
    Zinober, K.
    Scherzer, T. -M.
    Brillet, R.
    Ferenci, P.
    Pawlotsky, J. -M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S289 - S290
12